Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

This study has been completed.
Catalyst Pharmaceuticals, Inc.
Information provided by:
New York University School of Medicine Identifier:
First received: September 10, 2007
Last updated: April 7, 2008
Last verified: April 2008
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2007
  Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):